Saccharomyces Boulardii in Helicobacter Pylori Eradication in Children: A Randomized Trial From Iran

BACKGROUND: Helicobacter pylori infects around 50% of the human population and is asymptomatic in 70% of the cases. H. pylori eradication in childhood will not only result in peptic symptoms relief, but will also prevent late-term complications such as cancer. Today, probiotics are being increasingl...

Descripción completa

Detalles Bibliográficos
Autores principales: Namkin, Kokab, Zardast, Mahmood, Basirinejad, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733292/
https://www.ncbi.nlm.nih.gov/pubmed/26848376
http://dx.doi.org/10.5812/ijp.3768
_version_ 1782412812638748672
author Namkin, Kokab
Zardast, Mahmood
Basirinejad, Fatemeh
author_facet Namkin, Kokab
Zardast, Mahmood
Basirinejad, Fatemeh
author_sort Namkin, Kokab
collection PubMed
description BACKGROUND: Helicobacter pylori infects around 50% of the human population and is asymptomatic in 70% of the cases. H. pylori eradication in childhood will not only result in peptic symptoms relief, but will also prevent late-term complications such as cancer. Today, probiotics are being increasingly studied in the treatment of gastrointestinal infections as an alternative or complement to antibiotics. OBJECTIVES: In this study we aimed to assess the effect of S. boulardii supplementation on H. pylori eradication among children in our region. PATIENTS AND METHODS: In this randomized double-blind placebo-controlled clinical trial 28 asymptomatic primary school children with a positive H. pylori stool antigen (HpSA) exam were randomly allocated into the study group, receiving Saccharomyces boulardii, and the control group receiving placebo capsules matched by shape and size, for one month. The children were followed up weekly and were reinvestigated four to eight weeks after accomplished treatment by HpSA testing. The significance level was set at P < 0.05. RESULTS: 24 children completed the study. The mean HpSA reduced from 0.40 ± 0.32 to 0.21 ± 0.27 in the study group, indicating a significant difference (P = 0.005). However, such difference was not observed in the control group (P = 0.89). Moreover, the HpSA titer showed a 0.019 ± 0.19 decrease in the study group whereas the same value was 0.0048 ± 0.12 for the controls, again stating a significant difference (P = 0.01). CONCLUSIONS: Saccharomyces boulardii has a positive effect on reducing the colonization of H. pylori in the human gastrointestinal system but is not capable of its eradication when used as single therapy.
format Online
Article
Text
id pubmed-4733292
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-47332922016-02-04 Saccharomyces Boulardii in Helicobacter Pylori Eradication in Children: A Randomized Trial From Iran Namkin, Kokab Zardast, Mahmood Basirinejad, Fatemeh Iran J Pediatr Research Article BACKGROUND: Helicobacter pylori infects around 50% of the human population and is asymptomatic in 70% of the cases. H. pylori eradication in childhood will not only result in peptic symptoms relief, but will also prevent late-term complications such as cancer. Today, probiotics are being increasingly studied in the treatment of gastrointestinal infections as an alternative or complement to antibiotics. OBJECTIVES: In this study we aimed to assess the effect of S. boulardii supplementation on H. pylori eradication among children in our region. PATIENTS AND METHODS: In this randomized double-blind placebo-controlled clinical trial 28 asymptomatic primary school children with a positive H. pylori stool antigen (HpSA) exam were randomly allocated into the study group, receiving Saccharomyces boulardii, and the control group receiving placebo capsules matched by shape and size, for one month. The children were followed up weekly and were reinvestigated four to eight weeks after accomplished treatment by HpSA testing. The significance level was set at P < 0.05. RESULTS: 24 children completed the study. The mean HpSA reduced from 0.40 ± 0.32 to 0.21 ± 0.27 in the study group, indicating a significant difference (P = 0.005). However, such difference was not observed in the control group (P = 0.89). Moreover, the HpSA titer showed a 0.019 ± 0.19 decrease in the study group whereas the same value was 0.0048 ± 0.12 for the controls, again stating a significant difference (P = 0.01). CONCLUSIONS: Saccharomyces boulardii has a positive effect on reducing the colonization of H. pylori in the human gastrointestinal system but is not capable of its eradication when used as single therapy. Kowsar 2016-01-30 2016-02 /pmc/articles/PMC4733292/ /pubmed/26848376 http://dx.doi.org/10.5812/ijp.3768 Text en Copyright © 2016, Growth & Development Research Center. http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
spellingShingle Research Article
Namkin, Kokab
Zardast, Mahmood
Basirinejad, Fatemeh
Saccharomyces Boulardii in Helicobacter Pylori Eradication in Children: A Randomized Trial From Iran
title Saccharomyces Boulardii in Helicobacter Pylori Eradication in Children: A Randomized Trial From Iran
title_full Saccharomyces Boulardii in Helicobacter Pylori Eradication in Children: A Randomized Trial From Iran
title_fullStr Saccharomyces Boulardii in Helicobacter Pylori Eradication in Children: A Randomized Trial From Iran
title_full_unstemmed Saccharomyces Boulardii in Helicobacter Pylori Eradication in Children: A Randomized Trial From Iran
title_short Saccharomyces Boulardii in Helicobacter Pylori Eradication in Children: A Randomized Trial From Iran
title_sort saccharomyces boulardii in helicobacter pylori eradication in children: a randomized trial from iran
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733292/
https://www.ncbi.nlm.nih.gov/pubmed/26848376
http://dx.doi.org/10.5812/ijp.3768
work_keys_str_mv AT namkinkokab saccharomycesboulardiiinhelicobacterpylorieradicationinchildrenarandomizedtrialfromiran
AT zardastmahmood saccharomycesboulardiiinhelicobacterpylorieradicationinchildrenarandomizedtrialfromiran
AT basirinejadfatemeh saccharomycesboulardiiinhelicobacterpylorieradicationinchildrenarandomizedtrialfromiran